Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
38
ZIMV Quote, Financials, Valuation and Earnings
Last price:
$8.63
Seasonality move
:
-22.17%
Day range:
$8.34 - $8.89
52-week range:
$8.15 - $22.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.54x
P/B ratio:
0.62x
Volume:
218.1K
Avg. volume:
130.8K
1-year change:
-54.42%
Market cap:
$243.5M
Revenue:
$449.7M
EPS (TTM):
-$0.71
Analysts' Opinion
-
Consensus RatingZimVie has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.67, ZimVie has an estimated upside of 33.79% from its current price of $8.72.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 100% downside risk from its current price of $8.72.
Fair Value
-
According to the consensus of 3 analysts, ZimVie has 33.79% upside to fair value with a price target of $11.67 per share.
ZIMV vs. S&P 500
-
Over the past 5 trading days, ZimVie has underperformed the S&P 500 by -8.17% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ZimVie does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ZimVie revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter ZimVie reported revenues of $112M.
Earnings Growth
-
ZimVie has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ZimVie reported earnings per share of -$0.05.
Enterprise value:
397.3M
EV / Invested capital:
--
Price / LTM sales:
0.54x
EV / EBIT:
164.94x
EV / Revenue:
0.90x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
69.22x
Price / Operating cash flow:
41.90x
Enterprise value / EBITDA:
10.75x
Gross Profit (TTM):
$287.6M
Return On Assets:
-2.3%
Net Income Margin (TTM):
-4.4%
Return On Equity:
-4.97%
Return On Invested Capital:
-2.9%
Operating Margin:
3.27%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $348.1M | $455.2M | $443.6M | $118.2M | $112M | |
| Gross Profit | $221.5M | $287M | $287.6M | $73.9M | $74M | |
| Operating Income | $1.9M | -$6.7M | $754K | $884K | $3.7M | |
| EBITDA | $105.6M | $72.5M | $36.9M | $5.9M | $13.2M | |
| Diluted EPS | -$2.60 | -$14.03 | -$0.71 | -$0.29 | -$0.05 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $549.1M | $504.2M | $455.1M | $250.7M | |
| Total Assets | -- | $1.8B | $1.6B | $1.2B | $745.8M | |
| Current Liabilities | -- | $219.5M | $196.5M | $169.6M | $117.1M | |
| Total Liabilities | -- | $961.8M | $844.5M | $783.3M | $350.7M | |
| Total Equity | -- | $812.5M | $743.6M | $388.3M | $395.1M | |
| Total Debt | -- | $555.9M | $522M | $509.1M | $220.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $27.3M | $32.8M | $11.8M | -$11.5M | -$13.9M | |
| Cash From Investing | -$26.4M | -$13.5M | $284.5M | -$4.1M | -$1.9M | |
| Cash From Financing | -$34.4M | -$16.2M | -$294.4M | -$1.4M | -$1.1M | |
| Free Cash Flow | $3M | $22M | $5.7M | -$13.7M | -$15.4M | |
ZIMV
Sector
Market Cap
$243.5M
$34.4M
Price % of 52-Week High
38.93%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-54.42%
-37.36%
Beta (5-Year)
--
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$9.18
200-day SMA
Sell
Level
$12.12
Bollinger Bands (100)
Sell
Level
8.52 - 11.54
Chaikin Money Flow
Sell
Level
-206.6K
20-day SMA
Sell
Level
$9.19
Relative Strength Index (RSI14)
Sell
Level
40.88
ADX Line
Sell
Level
35.72
Williams %R
Buy
Level
-80.2083
50-day SMA
Sell
Level
$9.06
MACD (12, 26)
Buy
Level
2.44
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Sell
Level
-550.6K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.5285)
Sell
CA Score
(Annual)
Level (-0.7482)
Buy
Beneish M-Score
(Annual)
Level (-2.6161)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (7.9677)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
Stock Forecast FAQ
In the current month, ZIMV has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The ZIMV average analyst price target in the past 3 months is $11.67.
-
Where Will ZimVie Stock Be In 1 Year?
According to analysts, the consensus estimate is that ZimVie share price will rise to $11.67 per share over the next 12 months.
-
What Do Analysts Say About ZimVie?
Analysts are divided on their view about ZimVie share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ZimVie is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is ZimVie's Price Target?
The price target for ZimVie over the next 1-year time period is forecast to be $11.67 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is ZIMV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ZimVie is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ZIMV?
You can purchase shares of ZimVie via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ZimVie shares.
-
What Is The ZimVie Share Price Today?
ZimVie was last trading at $8.63 per share. This represents the most recent stock quote for ZimVie. Yesterday, ZimVie closed at $8.72 per share.
-
How To Buy ZimVie Stock Online?
In order to purchase ZimVie stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
